Investor's Business Daily on MSN1d
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
Harmony Sciences shares plunged Wednesday after the FDA rejected its bread-and-butter drug as a treatment for a daytime sleepiness condition.
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a ...
Harmony Biosciences's sleep disorder treatment gets FDA Refuse to File letter
Harmony Biosciences' ( NASDAQ: HRMY) stock fell about 7.3% after U.S. FDA notified the company that it will not review the ...
Axsome Therapeutics targets multiple NDA submissions and pipeline advancements through 2025
Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...
Managed Healthcare Executive2d
Narcolepsy Treatments
An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for ...